Premium
Interferon‐γ secretion defects in haemophilia A patients receiving highly purified plasma‐derived or recombinant factor VIII
Author(s) -
K. NewtonNash Debra,
Tollerud David,
Guevarra Lucille,
C. Gill Joan
Publication year - 1996
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1996.d01-1924.x
Subject(s) - haemophilia a , recombinant dna , secretion , haemophilia , medicine , interferon , virology , immunology , pharmacology , chemistry , biochemistry , surgery , gene
The outcome of developing immune responses is influenced by interactions among a large and complex network of secreted cytokines. T‐cell secretion of interferon‐γ (IFN‐γ), tumour necrosis factor α (TNF‐α) and TNF‐β, or lymphotoxin contributes to the development of cell‐mediated immunity, whereas secretion of interleukin (IL)‐4, IL‐5 and IL‐6 contributes to development of humoral immunity. Humoral immunity to factor VIII (FVIII) develops in approximately 25% of severe haemophilia A patients. The aim of our research was to understand the underlying immune response to FVIII in patients with FVIII inhibitors. We report a defect in IFN‐γ secretion by peripheral blood mononuclear cells (PBMC) derived from haemophilia A patients, which was accompanied by a low level of mitogen‐induced proliferation and a significant decrease in the percentage of natural killer (NK) cells. All of the observed defects were found in haemophilia A patients, both with and without FVIII inhibitors, who were free of viral infection and had been treated predominantly or exclusively with monoclonal antibody‐purified or recombinant FVIII.